Literature DB >> 33621350

Three-dimensional multipath DenseNet for improving automatic segmentation of glioblastoma on pre-operative multimodal MR images.

Jie Fu1, Kamal Singhrao1, X Sharon Qi1, Yingli Yang1, Dan Ruan1, John H Lewis2.   

Abstract

PURPOSE: Convolutional neural networks have achieved excellent results in automatic medical image segmentation. In this study, we proposed a novel three-dimensional (3D) multipath DenseNet for generating the accurate glioblastoma (GBM) tumor contour from four multimodal pre-operative MR images. We hypothesized that the multipath architecture could achieve more accurate segmentation than a singlepath architecture.
METHODS: Two hundred and fifty-eight GBM patients were included in this study. Each patient had four MR images (T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR) and the manually segmented tumor contour. We built a 3D multipath DenseNet that could be trained to achieve an end-to-end mapping from four MR images to the corresponding GBM tumor contour. A 3D singlepath DenseNet was also built for comparison. Both DenseNets were based on the encoder-decoder architecture. All four images were concatenated and fed into a single encoder path in the singlepath DenseNet, while each input image had its own encoder path in the multipath DenseNet. The patient cohort was randomly split into a training set of 180 patients, a validation set of 39 patients, and a testing set of 39 patients. Model performance was evaluated using the Dice similarity coefficient (DSC), average surface distance (ASD), and 95% Hausdorff distance (HD95% ). Wilcoxon signed-rank tests were conducted to assess statistical significances.
RESULTS: The singlepath DenseNet achieved the DSC of 0.911 ± 0.060, ASD of 1.3 ± 0.7 mm, and HD95% of 5.2 ± 7.1 mm, while the multipath DenseNet achieved the DSC of 0.922 ± 0.041, ASD of 1.1 ± 0.5 mm, and HD95% of 3.9 ± 3.3 mm. The P-values of all Wilcoxon signed-rank tests were less than 0.05.
CONCLUSIONS: Both DenseNets generated GBM tumor contours in good agreement with the manually segmented contours from multimodal MR images. The multipath DenseNet achieved more accurate tumor segmentation than the singlepath DenseNet. Here presented the 3D multipath DenseNet that demonstrated an improved accuracy over comparable algorithms in the clinical task of GBM tumor segmentation.
© 2021 American Association of Physicists in Medicine.

Entities:  

Keywords:  3D CNN; GBM tumor segmentation; multipath architecture

Mesh:

Year:  2021        PMID: 33621350     DOI: 10.1002/mp.14800

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  An Automatic Deep Learning-Based Workflow for Glioblastoma Survival Prediction Using Preoperative Multimodal MR Images: A Feasibility Study.

Authors:  Jie Fu; Kamal Singhrao; Xinran Zhong; Yu Gao; Sharon X Qi; Yingli Yang; Dan Ruan; John H Lewis
Journal:  Adv Radiat Oncol       Date:  2021-07-01

2.  Automated Detection of Brain Tumor through Magnetic Resonance Images Using Convolutional Neural Network.

Authors:  Sahar Gull; Shahzad Akbar; Habib Ullah Khan
Journal:  Biomed Res Int       Date:  2021-11-30       Impact factor: 3.411

3.  Study on the Grading Model of Hepatic Steatosis Based on Improved DenseNet.

Authors:  Ruwen Yang; Yaru Zhou; Weiwei Liu; Hongtao Shang
Journal:  J Healthc Eng       Date:  2022-03-17       Impact factor: 2.682

4.  Geometric and Dosimetric Evaluation of the Automatic Delineation of Organs at Risk (OARs) in Non-Small-Cell Lung Cancer Radiotherapy Based on a Modified DenseNet Deep Learning Network.

Authors:  Fuli Zhang; Qiusheng Wang; Anning Yang; Na Lu; Huayong Jiang; Diandian Chen; Yanjun Yu; Yadi Wang
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

Review 5.  Applications of Artificial Intelligence Based on Medical Imaging in Glioma: Current State and Future Challenges.

Authors:  Jiaona Xu; Yuting Meng; Kefan Qiu; Win Topatana; Shijie Li; Chao Wei; Tianwen Chen; Mingyu Chen; Zhongxiang Ding; Guozhong Niu
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.